List of Excipients in API momelotinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing momelotinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| GlaxoSmithKline LLC | OJJAARA | momelotinib | 81864-103 | CELLULOSE, MICROCRYSTALLINE | 2030-09-15 |
| GlaxoSmithKline LLC | OJJAARA | momelotinib | 81864-103 | FERRIC OXIDE RED | 2030-09-15 |
| GlaxoSmithKline LLC | OJJAARA | momelotinib | 81864-103 | FERRIC OXIDE YELLOW | 2030-09-15 |
| GlaxoSmithKline LLC | OJJAARA | momelotinib | 81864-103 | LACTOSE MONOHYDRATE | 2030-09-15 |
| GlaxoSmithKline LLC | OJJAARA | momelotinib | 81864-103 | MAGNESIUM STEARATE | 2030-09-15 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for momelotinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
momelotinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
momelotinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
momelotinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
momelotinib drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
momelotinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
momelotinib drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
momelotinib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYL GALLATE
momelotinib drug variants containing PROPYL GALLATE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing PROPYL GALLATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
momelotinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A CORN
momelotinib drug variants containing SODIUM STARCH GLYCOLATE TYPE A CORN
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
momelotinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
momelotinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | momelotinib | 81864-103 |
| >Company | >Ingredient | >NDC |
momelotinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
